Showing 5501-5510 of 21485 results for "".
- Dermatology Residents Show Gains After Targeted Topical Formulation Educationhttps://reachmd.com/news/dermatology-residents-show-gains-after-targeted-topical-formulation-education/2486095/A small survey-based study found that dermatology residents from 3 training programs reported limited formal education in topical vehicle formulation science, but showed improved comfort, confidence, and knowledge after a targeted educational intervention.
- Conversational AI (AMIE) in Urgent Care: Feasibility and Early Findingshttps://reachmd.com/news/conversational-ai-amie-in-urgent-care-feasibility-and-early-findings/2486067/A recent report describes a prospective, single-arm feasibility study that placed Google’s conversational diagnostic AI, the Articulate Medical Intelligence E
- Racial and Biological Diversity in Early Alzheimer Brain Markershttps://reachmd.com/news/racial-and-biological-diversity-in-early-alzheimer-brain-markers/2486071/Investigators working within the Health and Aging Brain Study–Health Disparities (HABS-HD) imaging effort reported that early Alzheimer disease–related biomarker patterns differed across ethnoracial groups
- ADorable-1 Trial Meets Endpoints for EBGLYSS in Children With Atopic Dermatitishttps://reachmd.com/news/adorable-1-trial-meets-endpoints-for-ebglyss-in-children-with-atopic-dermatitis/2486087/Eli Lilly and Company announced positive topline results from the phase 3 ADorable-1 trial of lebrikizumab-lbkz (Ebglyss) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis (AD), showing the therapy meeting its primary and sec
- Treatment Gaps and Outcomes for Adolescents with ADHD and SUDhttps://reachmd.com/news/news-summary-treatment-gaps-and-outcomes-for-adolescents-with-adhd-and-sud/2486070/A retrospective analysis of de-identified health records in people ages 15–25 with ADHD and substance use disorder (SUD) is describ
- NOA Longitudinal Validation On Home OCT for AMDhttps://reachmd.com/news/noa-longitudinal-validation-on-home-oct-for-amd/2486082/Longitudinal home OCT data were used to evaluate whether an artificial intelligence system can distinguish meaningful disease-activity change from stability when patients self-image frequently outside the clinic.
- FINERENONE (KERENDIA) Meets Primary Endpoint in FIND‑CKDhttps://reachmd.com/news/finerenone-kerendia-meets-primary-endpoint-in-findckd/2486094/Bayer reported that the Phase III FIND‑CKD study met its predefined primary endpoint, describing a statistically signif
- OFDI Shows Acute Thrombus and Healed Plaque in Symptomatic Femoropopliteal Lesionshttps://reachmd.com/news/ofdi-shows-acute-thrombus-and-healed-plaque-in-symptomatic-femoropopliteal-lesions/2486074/A recent American Journal of Cardiology abstract describes the use of optical frequency domain imaging (OFDI) in symptomatic femoropoplit
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://reachmd.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Plasmid Backbones Drive Global E. Coli Resistome Structurehttps://reachmd.com/news/plasmid-backbones-drive-global-e-coli-resistome-structure/2486058/Investigators report a plasmidome-resolved resistome analysis of 9700 Escherichia coli genomes, examining where resistance genes localize on plasmids versus chromosomes and how recurring plasmid